Scholarlink

<p>Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used to treat type 2 diabetes and manage weight in individuals with obesity or who are overweight. Semaglutide was found to reduce COVID-19-related mortality risk in a secondary analysis of the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial. We previously demonstrated that diabetes and obesity are associated with higher risks of COVID-19-related mortality in the general population. Using this existing cohort, we found that semaglutide use was associated with a significant 49% reduction in the risk of COVID-19-related death. Diabetes and obesity were linked to higher mortality risk, but an E-value of 3.31 suggests that unmeasured confounders would need to be strong to negate the observed association. These findings suggest that further investigation is warranted into the potential role of semaglutide in reducing risks associated with other causes of death.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Semaglutide and COVID-19 mortality risk

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Emily Tang,
  • Benjamin F. Arnold,
  • Nisha R. Acharya

摘要

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used to treat type 2 diabetes and manage weight in individuals with obesity or who are overweight. Semaglutide was found to reduce COVID-19-related mortality risk in a secondary analysis of the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial. We previously demonstrated that diabetes and obesity are associated with higher risks of COVID-19-related mortality in the general population. Using this existing cohort, we found that semaglutide use was associated with a significant 49% reduction in the risk of COVID-19-related death. Diabetes and obesity were linked to higher mortality risk, but an E-value of 3.31 suggests that unmeasured confounders would need to be strong to negate the observed association. These findings suggest that further investigation is warranted into the potential role of semaglutide in reducing risks associated with other causes of death.